Insider · CIK 0001488668

Epstein David M.

Reports to the SEC for 4 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001488668

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-10	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2025-06-04	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+26K sh	—	—	26,000
2024-08-14	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+52K sh	—	—	52,000
2024-08-06	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+1,866 sh	—	—	1,866
2023-06-27	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−25K sh	$6.70	−$168K	671,423
2023-02-13	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, SEE REMARKS	AAward	+420K sh	—	—	420,000
2022-02-15	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, SEE REMARKS	AAward	+300K sh	—	—	300,000
2021-02-17	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, SEE REMARKS	AAward	+225K sh	—	—	225,000
2021-01-04	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	−3,000 sh	—	—	230,116
2021-01-04	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−2,015 sh	$31.80	−$64.1K	696,423
2021-01-04	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−9,985 sh	$30.99	−$309K	698,438
2021-01-04	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	+3,000 sh	$6.42	+$19.3K	708,423
2020-12-15	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	−2,500 sh	—	—	233,116
2020-12-15	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	+2,500 sh	$6.42	+$16.1K	705,423
2020-12-01	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	+3,000 sh	$6.42	+$19.3K	714,923
2020-12-01	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−10.9K sh	$32.64	−$357K	704,000
2020-12-01	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−1,077 sh	$33.45	−$36K	702,923
2020-12-01	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	−3,000 sh	—	—	235,616
2020-11-02	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	+3,000 sh	$6.42	+$19.3K	723,923
2020-11-02	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−83 sh	$31.88	−$2,645.625	711,923
2020-11-02	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	−3,000 sh	—	—	238,616
2020-11-02	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−11.9K sh	$31.13	−$371K	712,006
2020-10-01	BDTXBlack Diamond Therapeutics, Inc.S Sale	Director, SEE REMARKS	SSale	−12K sh	$30.33	−$364K	720,923
2020-10-01	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	+3,000 sh	$6.42	+$19.3K	732,923
2020-10-01	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, SEE REMARKS	MExercise/Conversion	−3,000 sh	—	—	241,616
2020-02-03	BDTXBlack Diamond Therapeutics, Inc.C Conversion	Director, SEE REMARKS	CConversion	+23.1K sh	—	—	23,090
2020-02-03	BDTXBlack Diamond Therapeutics, Inc.C Conversion	Director, SEE REMARKS	CConversion	+243K sh	—	—	725,569
2020-02-03	BDTXBlack Diamond Therapeutics, Inc.C Conversion	Director, SEE REMARKS	CConversion	+4,354 sh	—	—	729,923
2020-02-03	BDTXBlack Diamond Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, SEE REMARKS	CConversion	−733K sh	—	—	0
2020-02-03	BDTXBlack Diamond Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, SEE REMARKS	CConversion	−69.6K sh	—	—	0
2020-02-03	BDTXBlack Diamond Therapeutics, Inc. · Series B Preferred StockC Conversion	Director, SEE REMARKS	CConversion	−13.1K sh	—	—	0
2020-01-29	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, SEE REMARKS	AAward	+279K sh	—	—	278,532
2014-10-14	MetaStat, Inc.A Award	Director	AAward	+105K sh	—	—	217,435
2014-07-22	MetaStat, Inc.A Award	Director	AAward	+12.5K sh	—	—	112,500
2014-07-14	MetaStat, Inc.A Award	Director	AAward	+188K sh	$1.10	+$207K	188,182
2014-07-14	MetaStat, Inc.Warrants to purchase common stockA Award	Director	AAward	+104K sh	—	—	103,500
2014-06-30	MetaStat, Inc.Warrants to purchase common stockA Award	Director	AAward	+21.5K sh	—	—	125,000
2014-06-30	MetaStat, Inc.A Award	Director	AAward	+39.1K sh	$1.10	+$43K	227,223
2010-06-07	OSI PHARMACEUTICALS INCU Disposition from Tender	Sr. VP and CSO, Oncology	UDisposition from Tender	−8 sh	$57.50	−$460	0
2010-06-03	OSI PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−22.5K sh	$57.50	−$1.29M	0
2010-06-03	OSI PHARMACEUTICALS INCD Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−9,809 sh	$57.50	−$564K	3,539
2010-06-03	OSI PHARMACEUTICALS INCU Disposition from Tender	Sr. VP and CSO, Oncology	UDisposition from Tender	−3,531 sh	$57.50	−$203K	8
2010-06-03	OSI PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−7,084 sh	$57.50	−$407K	0
2010-06-03	OSI PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−4,000 sh	$57.50	−$230K	0
2010-06-03	OSI PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−17.5K sh	$57.50	−$1.01M	0
2010-06-03	OSI PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Sr. VP and CSO, Oncology	DDisposition to Issuer	−11.3K sh	$57.50	−$647K	0
2010-05-01	OSI PHARMACEUTICALS INCF Tax Payment	Sr. VP and CSO, Oncology	FTax Payment	−906 sh	$58.67	−$53.2K	13,340

Recent filings

Accepted (ET)
Jun 304
Epstein David M.0001140361-26-027007
SEC(opens sec.gov)
Jun 64
Epstein David M.0001140361-25-021792
SEC(opens sec.gov)
Aug 164
Epstein David M.0001140361-24-037713
SEC(opens sec.gov)
Aug 84
Epstein David M.0001140361-24-036417
SEC(opens sec.gov)
Jun 284
Epstein David M.0001415889-23-010388
SEC(opens sec.gov)
Feb 154
Epstein David M.0001104659-23-022387
SEC(opens sec.gov)
Feb 174
Epstein David M.0001415889-22-001517
SEC(opens sec.gov)
Feb 194
Epstein David M.0000899243-21-007431
SEC(opens sec.gov)
Jan 64
Epstein David M.0000899243-21-000741
SEC(opens sec.gov)
Dec 164
Epstein David M.0000899243-20-034186
SEC(opens sec.gov)
Dec 34
Epstein David M.0000899243-20-032670
SEC(opens sec.gov)
Nov 34
Epstein David M.0000899243-20-030313
SEC(opens sec.gov)

Companies

Address

C/O GYRE THERAPEUTICS, INC. 12730 HIGH BLUFF DRIVE, SUITE 250

SAN DIEGO, CA, 92130